Detalhe da pesquisa
1.
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Proc Natl Acad Sci U S A
; 110(32): E2987-96, 2013 Aug 06.
Artigo
Inglês
| MEDLINE | ID: mdl-23882082
2.
Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.
J Biol Chem
; 285(51): 40362-72, 2010 Dec 17.
Artigo
Inglês
| MEDLINE | ID: mdl-20937841
3.
Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.
Cancer Immunol Res
; 3(2): 173-83, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25387893
4.
Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.
Mol Cancer Ther
; 13(2): 540-52, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24258345